Fig. 4. Surface proteomic signatures of lenalidomide resistance.

A In vitro-evolved lenalidomide-resistant H929 and OPM-2 lines were analyzed by cell-surface proteomics with comparison to parental lines by SILAC quantification (n = 4 biological replicates; heavy and light channels swapped for two replicates each). Significantly-changed proteins in blue (log₂-fold change > |1|; p < 0.05 by t-test), with only CD33 and PTPRC/CD45 showing common changes between the two lines. Source data in Supplementary Data 6. B MMRF CoMMpass patient transcript data confirms significant increase in CD33 and PTPRC at first relapse versus diagnosis (Release IA14, n = 50 patients), suggesting that increases in these surface proteins is driven by IMiD resistance. For B, upper and lower hinges correspond to 25 and 75 percentiles, center line indicates the median, and upper and lower whiskers extend to highest and lowest values within 1.5* IQR of the hinge.